Recent News

• 06.09.2025 - Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations
• 06.09.2025 - Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations
• 05.27.2025 - Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer
• 05.27.2025 - Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer
• 05.15.2025 - Palvella’s First Quarter 2025 Financial Results and Corporate Update Conference Call
• 05.15.2025 - Palvella’s First Quarter 2025 Financial Results and Corporate Update Conference Call
• 05.15.2025 - Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
• 05.15.2025 - Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
• 05.08.2025 - Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025
• 05.08.2025 - Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

Recent Filings

• 06.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.03.2025 - 3 Initial statement of beneficial ownership of securities
• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.15.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.15.2025 - 8-K Current report
• 05.15.2025 - EX-99.1 EX-99.1
• 04.30.2025 - ARS Annual Report to Security Holders
• 04.30.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material